RARE DISEASE
Uremic pruritus
Uremic pruritus
Uremic pruritus
Drug discovery
1
drug
With orphan designation
Overview
Uremic pruritus (UP), a chronic itch affecting 15-70% of chronic kidney disease (CKD) and end-stage renal disease (ESRD) patients, arises from immune dysregulation, peripheral neuropathy, and opioid system imbalance [1][5][7]. It manifests as generalized or localized itching without primary skin lesions, often worsening at night [6][12]. Diagnosis requires exclusion of other pruritic conditions [6][12]. Management combines optimized dialysis efficiency [1][6], topical therapies, gabapentinoids [3][5], and newer κ-opioid agonists [3][5], though treatment response remains variable [9].
Burden
Reduces quality of life through sleep disruption (53% of patients) [2][5], depression [2][6], and social withdrawal [1]
Independent mortality risk factor (17-22% increased risk) [1][6][12], linked to cardiovascular events and infections [1][15]
Underreported by 17% of patients, leading to undertreatment [1][2]
Categories: rare skin diseases
Research Papers
530 drug discovery papers about Uremic pruritus, with 1 first-in-class and 3 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
530 drug discovery papers about Uremic pruritus, with 1 first-in-class and 3 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-08-12 | Topical regimens for the management of uremic pruritus
Uremic pruritus (UP), also known as chronic kidney disease-associated pruritus, is a distressing condition affecting patients with end-stage renal disease. Characterized by persistent itching, it significantly impacts patients’ quality of life, leading to sleep disturbances, emotional distress, and decreased overall well-being. Although the exact pathophysiology remains uncertain, immune dysregulation, reduced stratum corneum hydration, and altered neurogenic inflammation contribute to UP. Consequently, treating UP poses a significant challenge. Among therapeutic regimens, topical regimens have been shown to effectively alleviate UP. Various topical formulations, including urea-based, physiological lipids, natural oils, capsaicin, anesthetics and glycerin-containing emollients, have demonstrated benefits in amelioration of pruritic symptoms. Clinical studies suggest that consistent application of emollients can minimize skin dryness and relieve pruritus. This review summarizes key clinical findings on the topical therapeutic regimens for UP.
2026-08-05 | Exploratory Analysis of Pruritus and Sleep Outcomes After LCR35 Supplementation in Maintenance Hemodialysis: A Randomized, Open-Label Controlled Study
Background/Objectives: Uremic pruritus and sleep disturbance commonly coexist in patients receiving maintenance hemodialysis. This analysis examined whether supplementation with Lactobacillus casei var. rhamnosus LCR35 was associated with changes in pruritus and sleep outcomes. Methods: This 12-week randomized, open-label, controlled study included 78 patients receiving maintenance hemodialysis who were assigned to LCR35 supplementation (n = 38; three sachets daily) or usual care without probiotic supplementation (n = 40). No placebo was used. Outcomes were Pittsburgh Sleep Quality Index (PSQI) and 5-D Itch Scale results. We used analysis of covariance (ANCOVA) for between-group analyses, with the week-12 score as the dependent variable and the corresponding baseline score as a covariate. Results: In the LCR35 group, descriptive improvements were observed in the 5-D Itch Scale and selected PSQI outcomes. However, none of the baseline-adjusted between-group differences was statistically significant: for 5-D Itch Scale, −1.48 (95% confidence interval (CI), −3.64 to 0.68; p = 0.176); for global PSQI, −0.80 (95% CI, −2.09 to 0.50; p = 0.225); for PSQI sleep disturbance, −0.07 (95% CI, −0.27 to 0.13; p = 0.482); and use of sleep medications, −0.28 (95% CI, −0.67 to 0.12; p = 0.163). In the LCR35 group, the exploratory association between changes in pruritus and the PSQI sleep-disturbances component was significant before, but not after, false-discovery-rate (FDR) correction (p = 0.007; FDR q = 0.055). Conclusions: Our preliminary findings raised the possibility that LCR35 might modestly influence pruritus and specific sleep disturbances. However, our results do not firmly establish a treatment effect, nor a patient phenotype most likely to benefit.
2026-08-03 | The neuroimmune architecture of uremic pruritus: mechanisms and therapeutic targeting.
Chronic kidney disease-associated pruritus (CKD-aP) remains a prevalent and burdensome symptom whose management is often empirical and only partially effective. Its pathophysiology appears to arise from interacting systemic, cutaneous, neural, and central mechanisms rather than from a single dominant pathway. In this review, we synthesize the evidence for a broader neuroimmune framework encompassing retained uremic solutes, microinflammation, xerosis and barrier dysfunction, immune dysregulation, neuropathic sensitization, opioid imbalance, and neuropeptide signaling. On this basis, we propose a four-node organizing model-Peripheral Neuroimmune Synapse (Node I), Neural Transmission and Hyperexcitability (Node II), Central Opioid Modulation (Node III), and Substance P/NK-1 Amplification (Node IV)-to translate mechanistic complexity into clinically intelligible domains. This model is intended as a pragmatic and hypothesis-generating framework, not as a validated endotyping system. Framed this way, it may help contextualize the observed benefits of therapies such as gabapentinoids and difelikefalin, clarify the limited performance of traditional antihistamine-based strategies, and support a more structured approach to bedside phenotyping and future enrichment-based trials. Prospective validation remains necessary before mechanism-guided therapeutic matching can be recommended as routine clinical practice.
2026-07-24 | Montelukast Versus Gabapentin for Uremic Pruritus in Twice-Weekly Hemodialysis Patients: A 52-Week Prospective Non-Randomized Open-Label Comparative Study.
Uremic pruritus (UP) remains a common and distressing complication in patients with end-stage renal disease (ESRD) receiving maintenance hemodialysis. The burden is particularly pronounced in low- and middle-income countries where twice-weekly hemodialysis is frequently practiced because of resource limitations. Gabapentin is widely used for the treatment of uremic pruritus; however, its use is often limited by central nervous system adverse effects and poor tolerability in older dialysis populations. Montelukast, a leukotriene receptor antagonist with anti-inflammatory properties, has been proposed as a potential alternative therapy. This study aimed to evaluate the comparative efficacy and safety of montelukast versus gabapentin for the treatment of uremic pruritus in patients receiving twice-weekly hemodialysis, with extended follow-up over 52 weeks. This prospective, open-label, non-randomized comparative study enrolled 195 adult patients with refractory uremic pruritus receiving twice-weekly hemodialysis. Participants were allocated to receive either montelukast or gabapentin based on predefined clinical and demographic criteria, including physician discretion and patient-specific factors. Clinical follow-up was conducted at 2, 4, 8, 12, 24, and 52 weeks. Pruritus severity was assessed using the Visual Analogue Scale (VAS). The primary outcome was change in Visual Analogue Scale score from baseline. Secondary outcomes included adverse events, treatment tolerability, need for dose escalation, and treatment discontinuation. A total of 176 patients completed the 52-week follow-up (montelukast, n = 91; gabapentin, n = 85). Baseline pruritus severity was comparable between the montelukast and gabapentin groups (mean VAS score 7.26 ± 1.56 vs. 7.41 ± 1.67, p = 0.54). Both treatments produced significant reductions in Visual Analogue Scale scores from baseline throughout the 52-week follow-up (p < 0.001 for both groups). Dose escalation was required in 38 patients (44.7%) receiving gabapentin within the first 6 weeks of therapy. Adverse events occurred significantly more frequently in the gabapentin group than in the montelukast group; 6 histories of falls and 11 treatment discontinuations due to adverse effects. Frequent adverse events reported in the montelukast group were abdominal pain and headache (17 and 14 episodes, respectively); whereas in the gabapentin group the common side effects were somnolence (39 incidence), fatigue (n = 21), dizziness (n = 17), and cognitive slowing (n = 16). Although gabapentin achieved modestly greater reductions in Visual Analogue Scale scores at selected follow-up time points, the absolute between-group differences remained below the predefined minimum clinically important difference of 1.0 VAS point. Montelukast provided sustained clinically meaningful improvement in uremic pruritus with substantially fewer treatment-related adverse events and superior tolerability than gabapentin. Although gabapentin achieved slightly greater reductions in pruritus severity at selected time points, these differences did not exceed the predefined minimum clinically important difference of 1.0 VAS point. Montelukast represents a practical and well-tolerated therapeutic option for patients receiving twice-weekly hemodialysis, particularly in resource-limited settings.
2026-06-30 | Effects of a moisturizer on uremic xerosis in patients undergoing hemodialysis
Purpose: Xerosis and pruritus are common dermatological complications in patients undergoing maintenance hemodialysis. However, evidence supporting the effectiveness of moisturizers in this population remains limited. This study evaluated the effects of a topical moisturizer on uremic xerosis and skin hydration in patients undergoing hemodialysis.Methods: We enrolled 21 patients undergoing maintenance hemodialysis who had skin dryness and itching; 20 completed the 4-week intervention and were included in the analysis. The participants applied a moisturizer containing ceramide NP, a ceramide composed of non-hydroxy fatty acids (N) and phytosphingosine (P), twice daily to the abdomen and right shin for 4 weeks. Skin hydration, transepidermal water loss (TEWL), erythema index, and melanin index were measured along with clinical assessments, including modified Eczema Area and Severity Index (mEASI) and Investigator’s Global Assessment (IGA), and patient-reported satisfaction.Results: Skin hydration increased significantly at weeks 2 and 4 at both sites compared to baseline (all P< 0.0001), whereas TEWL did not change significantly at either site. The mEASI score in the abdomen decreased significantly at week 4 (P= 0.012). Although IGA improvement was more frequent at week 4, the difference was not statistically significant. Overall, 85% of the patients reported satisfaction with symptom improvement.Conclusion: Regular application of a moisturizer was associated with a preliminary improvement in stratum corneum hydration and xerosis-related symptoms in patients undergoing hemodialysis, suggesting its potential role as a practical skin care intervention.
2026-08-12 | Topical regimens for the management of uremic pruritus
Uremic pruritus (UP), also known as chronic kidney disease-associated pruritus, is a distressing condition affecting patients with end-stage renal disease. Characterized by persistent itching, it significantly impacts patients’ quality of life, leading to sleep disturbances, emotional distress, and decreased overall well-being. Although the exact pathophysiology remains uncertain, immune dysregulation, reduced stratum corneum hydration, and altered neurogenic inflammation contribute to UP. Consequently, treating UP poses a significant challenge. Among therapeutic regimens, topical regimens have been shown to effectively alleviate UP. Various topical formulations, including urea-based, physiological lipids, natural oils, capsaicin, anesthetics and glycerin-containing emollients, have demonstrated benefits in amelioration of pruritic symptoms. Clinical studies suggest that consistent application of emollients can minimize skin dryness and relieve pruritus. This review summarizes key clinical findings on the topical therapeutic regimens for UP.
2026-08-05 | Exploratory Analysis of Pruritus and Sleep Outcomes After LCR35 Supplementation in Maintenance Hemodialysis: A Randomized, Open-Label Controlled Study
Background/Objectives: Uremic pruritus and sleep disturbance commonly coexist in patients receiving maintenance hemodialysis. This analysis examined whether supplementation with Lactobacillus casei var. rhamnosus LCR35 was associated with changes in pruritus and sleep outcomes. Methods: This 12-week randomized, open-label, controlled study included 78 patients receiving maintenance hemodialysis who were assigned to LCR35 supplementation (n = 38; three sachets daily) or usual care without probiotic supplementation (n = 40). No placebo was used. Outcomes were Pittsburgh Sleep Quality Index (PSQI) and 5-D Itch Scale results. We used analysis of covariance (ANCOVA) for between-group analyses, with the week-12 score as the dependent variable and the corresponding baseline score as a covariate. Results: In the LCR35 group, descriptive improvements were observed in the 5-D Itch Scale and selected PSQI outcomes. However, none of the baseline-adjusted between-group differences was statistically significant: for 5-D Itch Scale, −1.48 (95% confidence interval (CI), −3.64 to 0.68; p = 0.176); for global PSQI, −0.80 (95% CI, −2.09 to 0.50; p = 0.225); for PSQI sleep disturbance, −0.07 (95% CI, −0.27 to 0.13; p = 0.482); and use of sleep medications, −0.28 (95% CI, −0.67 to 0.12; p = 0.163). In the LCR35 group, the exploratory association between changes in pruritus and the PSQI sleep-disturbances component was significant before, but not after, false-discovery-rate (FDR) correction (p = 0.007; FDR q = 0.055). Conclusions: Our preliminary findings raised the possibility that LCR35 might modestly influence pruritus and specific sleep disturbances. However, our results do not firmly establish a treatment effect, nor a patient phenotype most likely to benefit.
2026-08-03 | The neuroimmune architecture of uremic pruritus: mechanisms and therapeutic targeting.
Chronic kidney disease-associated pruritus (CKD-aP) remains a prevalent and burdensome symptom whose management is often empirical and only partially effective. Its pathophysiology appears to arise from interacting systemic, cutaneous, neural, and central mechanisms rather than from a single dominant pathway. In this review, we synthesize the evidence for a broader neuroimmune framework encompassing retained uremic solutes, microinflammation, xerosis and barrier dysfunction, immune dysregulation, neuropathic sensitization, opioid imbalance, and neuropeptide signaling. On this basis, we propose a four-node organizing model-Peripheral Neuroimmune Synapse (Node I), Neural Transmission and Hyperexcitability (Node II), Central Opioid Modulation (Node III), and Substance P/NK-1 Amplification (Node IV)-to translate mechanistic complexity into clinically intelligible domains. This model is intended as a pragmatic and hypothesis-generating framework, not as a validated endotyping system. Framed this way, it may help contextualize the observed benefits of therapies such as gabapentinoids and difelikefalin, clarify the limited performance of traditional antihistamine-based strategies, and support a more structured approach to bedside phenotyping and future enrichment-based trials. Prospective validation remains necessary before mechanism-guided therapeutic matching can be recommended as routine clinical practice.
2026-07-24 | Montelukast Versus Gabapentin for Uremic Pruritus in Twice-Weekly Hemodialysis Patients: A 52-Week Prospective Non-Randomized Open-Label Comparative Study.
Uremic pruritus (UP) remains a common and distressing complication in patients with end-stage renal disease (ESRD) receiving maintenance hemodialysis. The burden is particularly pronounced in low- and middle-income countries where twice-weekly hemodialysis is frequently practiced because of resource limitations. Gabapentin is widely used for the treatment of uremic pruritus; however, its use is often limited by central nervous system adverse effects and poor tolerability in older dialysis populations. Montelukast, a leukotriene receptor antagonist with anti-inflammatory properties, has been proposed as a potential alternative therapy. This study aimed to evaluate the comparative efficacy and safety of montelukast versus gabapentin for the treatment of uremic pruritus in patients receiving twice-weekly hemodialysis, with extended follow-up over 52 weeks. This prospective, open-label, non-randomized comparative study enrolled 195 adult patients with refractory uremic pruritus receiving twice-weekly hemodialysis. Participants were allocated to receive either montelukast or gabapentin based on predefined clinical and demographic criteria, including physician discretion and patient-specific factors. Clinical follow-up was conducted at 2, 4, 8, 12, 24, and 52 weeks. Pruritus severity was assessed using the Visual Analogue Scale (VAS). The primary outcome was change in Visual Analogue Scale score from baseline. Secondary outcomes included adverse events, treatment tolerability, need for dose escalation, and treatment discontinuation. A total of 176 patients completed the 52-week follow-up (montelukast, n = 91; gabapentin, n = 85). Baseline pruritus severity was comparable between the montelukast and gabapentin groups (mean VAS score 7.26 ± 1.56 vs. 7.41 ± 1.67, p = 0.54). Both treatments produced significant reductions in Visual Analogue Scale scores from baseline throughout the 52-week follow-up (p < 0.001 for both groups). Dose escalation was required in 38 patients (44.7%) receiving gabapentin within the first 6 weeks of therapy. Adverse events occurred significantly more frequently in the gabapentin group than in the montelukast group; 6 histories of falls and 11 treatment discontinuations due to adverse effects. Frequent adverse events reported in the montelukast group were abdominal pain and headache (17 and 14 episodes, respectively); whereas in the gabapentin group the common side effects were somnolence (39 incidence), fatigue (n = 21), dizziness (n = 17), and cognitive slowing (n = 16). Although gabapentin achieved modestly greater reductions in Visual Analogue Scale scores at selected follow-up time points, the absolute between-group differences remained below the predefined minimum clinically important difference of 1.0 VAS point. Montelukast provided sustained clinically meaningful improvement in uremic pruritus with substantially fewer treatment-related adverse events and superior tolerability than gabapentin. Although gabapentin achieved slightly greater reductions in pruritus severity at selected time points, these differences did not exceed the predefined minimum clinically important difference of 1.0 VAS point. Montelukast represents a practical and well-tolerated therapeutic option for patients receiving twice-weekly hemodialysis, particularly in resource-limited settings.
2026-06-30 | Effects of a moisturizer on uremic xerosis in patients undergoing hemodialysis
Purpose: Xerosis and pruritus are common dermatological complications in patients undergoing maintenance hemodialysis. However, evidence supporting the effectiveness of moisturizers in this population remains limited. This study evaluated the effects of a topical moisturizer on uremic xerosis and skin hydration in patients undergoing hemodialysis.Methods: We enrolled 21 patients undergoing maintenance hemodialysis who had skin dryness and itching; 20 completed the 4-week intervention and were included in the analysis. The participants applied a moisturizer containing ceramide NP, a ceramide composed of non-hydroxy fatty acids (N) and phytosphingosine (P), twice daily to the abdomen and right shin for 4 weeks. Skin hydration, transepidermal water loss (TEWL), erythema index, and melanin index were measured along with clinical assessments, including modified Eczema Area and Severity Index (mEASI) and Investigator’s Global Assessment (IGA), and patient-reported satisfaction.Results: Skin hydration increased significantly at weeks 2 and 4 at both sites compared to baseline (all P< 0.0001), whereas TEWL did not change significantly at either site. The mEASI score in the abdomen decreased significantly at week 4 (P= 0.012). Although IGA improvement was more frequent at week 4, the difference was not statistically significant. Overall, 85% of the patients reported satisfaction with symptom improvement.Conclusion: Regular application of a moisturizer was associated with a preliminary improvement in stratum corneum hydration and xerosis-related symptoms in patients undergoing hemodialysis, suggesting its potential role as a practical skin care intervention.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
1 orphan drug designation for Uremic pruritus.
1 orphan drug designation for Uremic pruritus.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
(-)-17-(cyclopropylmethyl)-3,14 ß-dihydroxy-4,5 α-epoxy-6ß-[N-methyl-trans-3-(3-furyl) acrylamido] morphinan hydrochloride | small molecules | EMA | 2002-09-11 | — | Toray International Europe GmbH |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.